EGFR targeted theranostic Nanoemulsion for image-guided ovarian cancer therapy

Pharmaceutical Research

Volumn 32, Issue 8, 2015, Pages 2753-2763

  Ganta, Srinivas ^a,b   Singh, Amit ^b   Kulkarni, Praveen ^b   Keeler, Amanda W ^d   Piroyan, Aleksandr ^a,b   Sawant, Rupa R ^b   Patel, Niravkumar R ^a,b   Davis, Barbara ^a,b   Ferris, Craig ^b   O’Neal, Sara ^c,d   Zamboni, William ^c,d   Amiji, Mansoor M ^b   Coleman, Timothy P ^a,b,e,f  

^a Nemucore Medical Innovations Inc   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

^e Blue Ocean Biomanufacturing Inc   (United States)

^f Foundation for the Advancement of Personalized Medicine Manufacturing   (United States)

Author keywords

C6 ceramide; Gadolinium; Myrisplatin; Nanoemulsion; Ovarian cancer

Indexed keywords

CERAMIDE C 6; CERAMIDE DERIVATIVE; CISPLATIN; ENDOTHELIAL GROWTH FACTOR RECEPTOR; GADOLINIUM PENTETATE MEGLUMINE; GROWTH FACTOR RECEPTOR; MYRISPLATIN; PLATINUM DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CERAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GADOLINIUM; N-CAPROYLSPHINGOSINE; PLATINUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; FEMALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MONONUCLEAR PHAGOCYTE; MOUSE; NANOEMULSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVARY CANCER; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SURVIVAL TIME; THERANOSTIC NANOMEDICINE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; TUMOR VOLUME; VOLUME OF DISTRIBUTION; ZETA POTENTIAL; ANIMAL; DRUG EFFECTS; METABOLISM; MICROFLUIDICS; OVARIAN NEOPLASMS; PROCEDURES; SURVIVAL ANALYSIS; THROMBOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PLATELETS; CERAMIDES; DRUG DELIVERY SYSTEMS; FEMALE; GADOLINIUM; MICE; MICROFLUIDICS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PARTICLE SIZE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; THERANOSTIC NANOMEDICINE; TISSUE DISTRIBUTION;

EID: 84984999033     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1660-z     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. CA Cancer J Clin. 2013;63(1): 11-30.
2. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183-203.
3. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, et al. Long-termsurvival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer. 1991;27(11):1367-72.
4. Kartalou M, Essigmann JM. Mechanisms of resistance to cisplatin. Mutat Res. 2001;478(12):23-43.
5. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, et al. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005;93(6):678-87.
6. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9(3):389-93.
7. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19(3):311-30.
8. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov. 2003;2(5):347-60.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
10. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release Off J Control Release Soc. 2001;73(23):137-72.
11. Oberoi HS, Nukolova NV, Kabanov AV, Bronich TK. Nanocarriers for delivery of platinum anticancer drugs. Adv Drug Deliv Rev. 2013;65(1314):1667-85.
12. Stathopoulos GP. Liposomal cisplatin: a new cisplatin formulation. Anti-Cancer Drugs. 2010;21(8):732-6.
13. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Zuhowski EG, Pluim D, et al. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol. 2004;53(4): 329-36.
14. Ganta S, Singh A, Patel NR, Cacaccio J, Rawal YH, Davis BJ, et al. Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res. 2014;31(9):2490-502.
15. Ganta S, Talekar M, Singh A, Coleman TP, Amiji MM. Nanoemulsions in translational research-opportunities and challenges in targeted cancer therapy. AAPS PharmSciTech. 2014;15(3):694-708.
16. Sarker DK. Engineering of nanoemulsions for drug delivery. Curr Drug Deliv. 2005;2(4):297-310.
17. Ganta S, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in parenteral emulsion. Int J Pharm. 2008;360(12):115-21.
18. Ganta S, Deshpande D, Korde A, Amiji M. A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. Mol Membr Biol. 2010;27(7):260-73.
19. Ganta S, Sharma P, Paxton JW, Baguley BC, Garg S. Pharmacokinetics and pharmacodynamics of chlorambucil delivered in long-circulating nanoemulsion. J Drug Target. 2010;18(2): 125-33.
20. Ganta S, Singh A, Rawal Y, Cacaccio J, Patel NR, Kulkarni P, et al. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv. 2014:1-13. doi:10.3109/10717544.2014.923068
21. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release Off J Control Release Soc. 2000;65(12): 271-84.
22. Ganta S, Amiji M. Coadministration of Paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm. 2009;6(3):928-39.
23. Talekar M, Ganta S, Singh A, Amiji M, Kendall J, Denny WA, et al. Phosphatidylinositol 3-kinase inhibitor (PIK75) containing surface functionalized nanoemulsion for enhanced drug delivery, cytotoxicity and pro-apoptotic activity in ovarian cancer cells. Pharm Res. 2012;29(10):2874-86.
24. Ganta S, Devalapally H, Amiji M. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation. J Pharm Sci. 2010;99(11): 4630-41.
25. Maeda M, Sasaki T, Inventors; Sumitomo Pharmaceuticals Company Ltd, assignee. Liposoluble platinum (II) complex and preparation thereof patent 6, 613,7991. 2003.
26. Nagaraja TN, Croxen RL, Panda S, Knight RA, Keenan KA, Brown SL, et al. Application of arsenazo III in the preparation and characterization of an albumin-linked, gadolinium-based macromolecular magnetic resonance contrast agent. J Neurosci Methods. 2006;157(2):238-45.
27. Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, et al. Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res. 2002;8(9):2992-9.
28. Jamieson ER, Jacobson MP, Barnes CM, Chow CS, Lippard SJ. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B. J Biol Chem. 1999;274(18):12346-54.
29. Wong E, Giandomenico CM. Current status of platinum-based antitumor drugs. Chem Rev. 1999;99(9):2451-66.
30. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307-20.
31. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008;105(45):17356-61.
32. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A. 2011;108(5):1850-5.
33. Paraskar AS, Soni S, Chin KT, Chaudhuri P, Muto KW, Berkowitz J, et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A. 2010;107(28):12435-40.
34. Stathopoulos GP, Boulikas T. Lipoplatin formulation review article. J Drug Delivery. 2012;2012:581363.
35. Harrington KJ, Lewanski CR, Northcote AD, Whittaker J, Wellbank H, Vile RG, et al. Phase I-II study of pegylated liposomal cisplatin (SPI-077) in patients with inoperable head and neck cancer. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2001;12(4):493-6.
36. Cronin MT, Dearden JC, Duffy JC, Edwards R, Manga N, Worth AP, et al. The importance of hydrophobicity and electrophilicity descriptors in mechanistically-based QSARs for toxicological endpoints. SAR QSAR Environ Res. 2002;13(1):167-76.
37. Shen DW, Pouliot LM, Hall MD, Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev. 2012;64(3):706-21.
38. Milane L, Duan Z, Amiji M. Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm. 2011;8(1):185-203.
39. Song S, Liu D, Peng J, Sun Y, Li Z, Gu JR, et al. Peptide ligandmediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008;363(12):155-61.
40. Li Z, Zhao R, Wu X, Sun Y, Yao M, Li J, et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J Off Publ Fed Am Soc Exp Biol. 2005;19(14):1978-85